Ferring Makes Important Milestone For Microbiome With Rebyota Approval
Executive Summary
The microbiome therapy won approval for preventing recurrence of Clostridioides difficile infections, but an analyst said the future could be in more targeted approaches.
You may also be interested in...
Finch To Wind Down, Seek Value For Pipeline Assets And IP
Following two workforce cuts in 2022, Finch said it will cut its staff by 95%, halting a Phase III study of lead recurrent C. diff candidate CP101 and seeking to maximize shareholder value.
CDI Market Snapshot: Microbiome Therapies Begin Descent On Landscape
The recent US approval of Ferring’s microbiome-targeting Rebyota is set to change the treatment landscape for recurrent Clostridioides difficile infection and could be the proving ground for this class of agents. Rebyota is the first microbiome-targeting treatment to reach the market, but several promising candidates for the same indication are waiting in the wings.
Ferring’s Fecal Transplant Gets Through AdComm, Aided By Preference For Standardized Product
US FDA's Vaccines and Related Biological Products Advisory Committee endorses Rebyota for recurrent C. difficile infection; most panelists prefer a product whose manufacturing will be regulated, even one with lingering concerns about efficacy or safety, over the current landscape.